

April 11, 2008

Precision System Science, Co., Ltd.

PSS reaches agreement with Diagenode SA of Belgium and
Nippon Gene Co., Ltd. on developing and marketing of
Automated Epigenetic System

Precision System Science, Co., Ltd. (PSS) has agreed with Diagenode SA, a reagent manufacturer of Belgium and Nippon Gene Co., Ltd. (HQ: Chiyoda-ku, Tokyo) to collaborate on a the development of Automated Epigenetic System. Based on this world wide collaboration between the 3 partners, PSS will strengthen the development activities in the field of epigenetic, which has been increasingly activated in the cancer research market.

Epigenetics is the study of heritable changes in gene expression that occur without a change in DNA sequence. Epigenetics mechanisms include chromatin modification and DNA methylation. In Europe and the United States, there has been a great interest in the epigenetics as it plays an important role in cancer diagnostics and other applications. In particular, combination of chromatin immuno-precipitation and recently introduced high through-put sequencing technologies is rapidly expanding and the demand for automated system has become greater.

In order to meet the growing epigenetic market, PSS and its partners, Nippon Gene, a reagent maker, with whom PSS has had long business relationship, and Diagenode SA, who has distinguished experiences in reagent development for epigenetics, are developing automated epigenetic system, combining PSS instrument technology and Diagenode reagents. After testing the performance of PSS instrument with the Diagenode reagent at β -sites in Europe and USA, the system with necessary improvements will be introduced into the market.

###